wwikiqo
About

Funapide

Analgesic drug under development

Funapide

Funapide is a novel analgesic under development by Xenon Pharmaceuticals for the treatment of a variety of chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain. It acts as a small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker. Funapide was evaluated in humans in both oral and topical formulations, and as of July 2014, had reached phase IIb clinical trials. Development of the drug was discontinued in 2022.

Funapide
Funapide
Clinical data
Routes of
administration		By mouth, topical
ATC code
  • None
Identifiers
  • (7S)-1'-[[5-(trifluoromethyl)furan-2-yl]methyl]spiro[6H-furo[2,3-f][1,3]benzodioxole-7,3'-indole]-2'-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC22H14F3NO5
Molar mass429.351 g·mol−1
3D model (JSmol)
  • C1C2(C3=CC=CC=C3N(C2=O)CC4=CC=C(O4)C(F)(F)F)C5=CC6=C(C=C5O1)OCO6
  • InChI=1S/C22H14F3NO5/c23-22(24,25)19-6-5-12(31-19)9-26-15-4-2-1-3-13(15)21(20(26)27)10-28-16-8-18-17(7-14(16)21)29-11-30-18/h1-8H,9-11H2/t21-/m0/s1
  • Key:NEBUOXBYNAHKFV-NRFANRHFSA-N

Funapide (INN; former developmental codes TV-45070 and XEN402) is a novel analgesic under development by Xenon Pharmaceuticals (formerly in partnership with Teva Pharmaceutical Industries) for the treatment of a variety of chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain.[1][2][3][4] It acts as a small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker.[1][2][4] Funapide was evaluated in humans in both oral and topical formulations, and as of July 2014, had reached phase IIb clinical trials.[1][3] Development of the drug was discontinued in 2022.[5]

See also

References

  1. 1 2 3 Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA (August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–3699. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.
  2. 1 2 Ali Z, Palmer JE, Goli V (2013). "Anticonvulsants: Clinical". In McMahon S, Koltzenburg M, Tracey I, Turk DC (eds.). Wall & Melzack's Textbook of Pain (6 ed.). Elsevier Health Sciences. p. 508. ISBN 978-0-7020-4059-7. OCLC 1008841684.
  3. 1 2 "TV-45070: A Small Molecule for the Treatment of the Orphan Disease EM and Other Pain Disorders". Xenon Pharma. Archived from the original on 15 July 2013.
  4. 1 2 "Teva and Xenon Announce Teva's World Wide License of Xenon's Pain Drug XEN402". Xenon Pharma. 11 December 2012. Archived from the original on 26 July 2014. Retrieved 2014-07-20.
  5. ↑ "Funapide - Flexion Therapeutics". AdisInsight. Springer Nature Switzerland AG.


Funapide | wikiqo